Precision Diagnostics Fund Exceeds Target with £150m Close for Next-Gen Diagnostic Technologies
Precision Diagnostics Fund (PDF) has announced the final close of its inaugural fund, securing £150 million, significantly surpassing its initial £100 million target. The oversubscribed fund will primarily invest in European and UK-based start-ups developing innovative diagnostic technologies, from advanced imaging to liquid biopsies.

London-based venture capital firm, Precision Diagnostics Fund (PDF), has successfully closed its debut fund, raising an impressive £150 million. The oversubscribed fund, which initially aimed for £100 million, attracted strong interest from institutional investors, family offices, and strategic healthcare corporations keen to capitalise on the rapidly evolving diagnostics market.
PDF's mandate is to back early to growth-stage companies that are pioneering next-generation diagnostic tools and platforms. This includes areas such as advanced molecular diagnostics, point-of-care testing, novel imaging agents, and AI-driven analytical solutions. The firm's investment thesis is centred on technologies that promise to deliver earlier, more accurate, and less invasive disease detection.
Premium story
Create a free account for 3 premium articles a month
Free members read three premium pieces every month. Or go unlimited with Premium.
Create a free accountPremium
£29/month or £290/year
Unlimited premium analysis, The Analyst Note and the full archive.
Choose PremiumAlready a member? Sign in
Source: MedTwenty
Related stories

Investment & Markets
CMA invites comment on Intersurgical's planned purchase of Teleflex acute care and urology units

Investment & Markets
Tempus acquires Personalis in $1.5bn deal, deepening push into cancer genomics

Investment & Markets
KKR completes Envision restructuring at $7.0bn, wiping out earlier equity